OMER
Price
$16.88
Change
+$0.62 (+3.81%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.18B
21 days until earnings call
Intraday BUY SELL Signals
TOVX
Price
$0.19
Change
-$0.01 (-5.00%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
9.02M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OMER vs TOVX

OMER vs TOVX Comparison Chart in %
View a ticker or compare two or three
VS
OMER vs. TOVX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OMER is a StrongBuy and TOVX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for OMER with price predictions
Oct 21, 2026

OMER's RSI Indicator ascends from oversold territory

The RSI Indicator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 67 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

OMER moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for OMER entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.922) is normal, around the industry mean (2.988). P/E Ratio (8.469) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TOVX with price predictions
Oct 21, 2026

TOVX's RSI Oscillator slumps into oversold zone

The RSI Oscillator for TOVX moved into overbought territory on October 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

TOVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TOVX as a result. In 90 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for TOVX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 47 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

TOVX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TOVX crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TOVX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.740) is normal, around the industry mean (2.988). P/E Ratio (0.137) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (23.753) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TOVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
OMER vs TOVX: Fundamental Ratings
OMER
TOVX
OUTLOOK RATING
1..100
6877
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
1199
PRICE GROWTH RATING
1..100
3678
P/E GROWTH RATING
1..100
7418
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OMER's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for TOVX (60) in the null industry. This means that OMER’s stock grew somewhat faster than TOVX’s over the last 12 months.

OMER's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as TOVX (100) in the null industry. This means that OMER’s stock grew similarly to TOVX’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for TOVX (99) in the null industry. This means that OMER’s stock grew significantly faster than TOVX’s over the last 12 months.

OMER's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for TOVX (78) in the null industry. This means that OMER’s stock grew somewhat faster than TOVX’s over the last 12 months.

TOVX's P/E Growth Rating (18) in the null industry is somewhat better than the same rating for OMER (74) in the Biotechnology industry. This means that TOVX’s stock grew somewhat faster than OMER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OMERTOVX
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (OMER: $16.26 vs. TOVX: $0.20)
Brand notoriety: OMER and TOVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OMER: 46% vs. TOVX: 134%
Market capitalization -- OMER: $1.22B vs. TOVX: $9.02M
OMER [@Biotechnology] is valued at $1.22B. TOVX’s [@Biotechnology] market capitalization is $9.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OMER’s FA Score shows that 2 FA rating(s) are green while TOVX’s FA Score has 1 green FA rating(s).

  • OMER’s FA Score: 2 green, 3 red.
  • TOVX’s FA Score: 1 green, 4 red.
According to our system of comparison, OMER is a better buy in the long-term than TOVX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OMER’s TA Score shows that 4 TA indicator(s) are bullish while TOVX’s TA Score has 3 bullish TA indicator(s).

  • OMER’s TA Score: 4 bullish, 6 bearish.
  • TOVX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, OMER is a better buy in the short-term than TOVX.

Price Growth

OMER (@Biotechnology) experienced а -11.77% price change this week, while TOVX (@Biotechnology) price change was -6.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

OMER is expected to report earnings on Nov 12, 2026.

TOVX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
OMER
Daily Signal:
Gain/Loss:
TOVX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with GNPX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
-1.75%
GNPX - OMER
51%
Loosely correlated
-3.76%
VCYT - OMER
40%
Loosely correlated
+3.19%
INM - OMER
36%
Loosely correlated
+2.99%
TOVX - OMER
35%
Loosely correlated
-5.48%
ABSI - OMER
34%
Loosely correlated
+10.69%
More

TOVX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TOVX has been loosely correlated with GOVX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if TOVX jumps, then GOVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TOVX
1D Price
Change %
TOVX100%
-5.48%
GOVX - TOVX
54%
Loosely correlated
+2.25%
GNPX - TOVX
50%
Loosely correlated
-3.76%
VOR - TOVX
42%
Loosely correlated
-0.47%
TVRD - TOVX
41%
Loosely correlated
+2.82%
QNRX - TOVX
40%
Loosely correlated
-0.74%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HTZ2.070.15
+7.81%
Hertz Global Holdings
GMAB39.570.50
+1.28%
Genmab A/S ADS
BATRA55.12-0.05
-0.09%
Atlanta Braves Holdings
MYND0.19N/A
-1.61%
Myndai
CMPX0.81-0.02
-2.26%
Compass Therapeutics